Sotera Health Posts Strong Q1 2026 Growth, Reaffirms Full-Year Outlook
Event summary
- Q1 2026 net revenues increased 10.0% (6.5% constant currency) year-over-year.
- Net income of $27 million ($0.09 per diluted share) compared to a net loss of $13 million in Q1 2025.
- Adjusted EBITDA increased 10.5% (6.9% constant currency) year-over-year.
- Sterigenics and Nordion drove growth with 6.1% and 25.8% constant currency revenue growth, respectively.
- Company reaffirmed 2026 outlook for 5.0%-6.5% net revenue growth and 5.5%-7.0% Adjusted EBITDA growth.
The big picture
Sotera Health's strong Q1 2026 results reflect disciplined execution across its core segments, particularly Sterigenics and Nordion. The company's ability to reaffirm its full-year outlook despite regulatory and operational challenges underscores its strategic resilience. As a leading provider of mission-critical sterilization solutions, Sotera Health's performance is closely watched by investors in the healthcare services sector, particularly amid ongoing geopolitical and inflationary pressures.
What we're watching
- Segment Performance
- Whether Sterigenics and Nordion can sustain their growth momentum while Nelson Labs recovers from volume/mix challenges.
- CEO Transition
- How the planned CEO transition will impact strategic execution and investor confidence.
- Regulatory Risks
- The potential impact of evolving environmental, health, and safety regulations on operations and costs.
Related topics